Pharming Group files 2025 annual report and 20-F
Pharming Group N.V. has filed its 2025 Annual Report for the year ended December 31, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
6-K
Rhea-AI Filing Summary
Pharming Group N.V. has filed its 2025 Annual Report for the year ended December 31, 2025. The report is available via annualreport.pharming.com and the Investors/Financial documents section of the company’s website.
The company has also filed its 2025 Annual Report on Form 20-F with the U.S. SEC, which can be accessed through the Investors/SEC filings section on Pharming.com and the SEC website.
Key Terms
Form 6-K, Form 20-F, foreign private issuer, biopharmaceutical company, +1 more
5 terms
Form 6-K regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
Form 20-F regulatory
"Annual Report on Form 20-F with the U.S. Securities and Exchange Commission"
Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.
foreign private issuer regulatory
"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
biopharmaceutical company financial
"Pharming Group N.V. ... is a global biopharmaceutical company dedicated to transforming the lives of patients"
rare, debilitating, and life-threatening diseases medical
"dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Pharming Group (PHAR) announce in its April 2026 6-K filing?
Pharming Group announced it has filed its 2025 Annual Report and its Annual Report on Form 20-F. These documents cover the year ended December 31, 2025 and are now available through the company’s website and, for Form 20-F, through the SEC website.
Where can investors access Pharming Group’s 2025 Annual Report?
Investors can access Pharming Group’s 2025 Annual Report at annualreport.pharming.com. It is also available under the Investors/Financial documents section of the Pharming.com website, providing detailed information on the company’s operations and performance for the year ended December 31, 2025.
How can investors find Pharming Group’s 2025 Form 20-F filing?
Pharming Group’s 2025 Annual Report on Form 20-F is available under Investors/SEC filings on Pharming.com. It can also be accessed through the U.S. Securities and Exchange Commission website once filed, offering U.S. investors a standardized disclosure format.
What type of company is Pharming Group (PHAR)?
Pharming Group is a global biopharmaceutical company focused on rare, debilitating, and life-threatening diseases. It develops and commercializes a portfolio of innovative medicines, including small molecules and biologics, and is headquartered in Leiden, the Netherlands with many employees based in the U.S.
How can investors contact Pharming Group’s Investor Relations team?
Investors can contact Pharming Group’s Investor Relations through Michael Levitan, VP Investor Relations & Corporate Communications. He can be reached by phone at +1 (908) 705 1696 or by email at investor@pharming.com for further public information and investor-related inquiries.
Who handles media relations for Pharming Group in key regions?
Global media relations are handled by Saskia Mehring in Corporate Communications. In the U.S., Ethan Metelenis of Precision AQ represents Pharming, while in the Netherlands, Leon Melens of LifeSpring Life Sciences Communication supports media outreach, ensuring coverage in each core geography.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of April 2026
Commission File Number: 001-39822
Pharming Group N.V.
(Exact Name of Registrant as Specified in Its Charter)
Darwinweg 24
2333 CR Leiden
The Netherlands
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated April 2, 2026.
EXHIBIT INDEX
Exhibit No. | Description | |||||||
99.1 | Pharming Group announces the filing of its 2025 Annual Report and Form 20-F | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Pharming Group N.V. | |||||||||||
By: | /s/ Fabrice Chouraqui | ||||||||||
Name: | Fabrice Chouraqui | ||||||||||
Title: | CEO | ||||||||||
Date: April 2, 2026
Pharming Group announces the filing of its 2025 Annual Report and Form 20-F
Leiden, the Netherlands, April 2, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced the filing of its Annual Report for the year ended December 31, 2025. The Annual Report is available at annualreport.pharming.com and under Investors/Financial documents on the Pharming.com website.
The Company also announced the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC). The 2025 Annual Report on Form 20-F can be found under Investors/SEC filings on Pharming.com and through the SEC website once it has been filed.
About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S.
For more information, visit www.pharming.com and find us on LinkedIn.
For further public information, contact:
Investor Relations
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com
Media Relations
Global: Saskia Mehring, Corporate Communications Manager
T: +31 6 28 32 60 41
E: media.relations@pharming.com
U.S.: Ethan Metelenis (Precision AQ on behalf of Pharming)
T: +1 (917) 882-9038
Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)
T: +31 6 53 81 64 27